Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On August 14, 2025, Liminatus Pharma announced an update on its CD47 checkpoint inhibitor, IBA101, which is designed to synergize with PD-1/PD-L1 inhibitors. As patents for existing PD-1/PD-L1 therapies are set to expire, IBA101 offers a strategic opportunity to extend the life cycle of these therapies through new combination indications. The company highlights IBA101’s unique ability to activate innate immune responses without the cytopenia issues seen in earlier CD47 programs, positioning it as a valuable asset in the competitive immuno-oncology landscape.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the immuno-oncology industry, focusing on developing innovative therapies such as CD47 checkpoint inhibitors. The company is positioned to address the challenges faced by the PD-1/PD-L1 inhibitor market, which is nearing a patent cliff, by offering novel combination therapies.
Average Trading Volume: 599,393
Technical Sentiment Signal: Sell
Current Market Cap: $117.7M
For a thorough assessment of LIMN stock, go to TipRanks’ Stock Analysis page.